{
    "nct_id": "NCT04603495",
    "official_title": "A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients",
    "inclusion_criteria": "* Aged ≥ 18 years\n* Confirmed diagnosis of myelofibrosis (primary, post-polycythemia vera, or post essential thrombocythemia)\n* Adequate hematologic, renal, and hepatic function\n* Have at least 2 symptoms with an average score ≥ 3 or an average total score of ≥ 10 over the 7-day period prior to randomization using the MFSAF v4.0\n* Prognostic risk-factor score of Intermediate-1 or higher per Dynamic International Prognostic Scoring System (DIPSS) scoring system\n* Spleen volume of ≥ 450 cm^3\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Splenectomy or splenic irradiation in the previous 6 months\n* Chronic or active conditions and/or concomitant medication use that would prohibit treatment\n* Had prior treatment with any JAKi or BET inhibitor for treatment of a myeloproliferative neoplasm",
    "miscellaneous_criteria": ""
}